MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
11.59
-0.02
-0.17%
After Hours: 11.53 -0.06 -0.52% 19:55 09/28 EDT
OPEN
11.51
PREV CLOSE
11.61
HIGH
11.85
LOW
11.31
VOLUME
3.76M
TURNOVER
--
52 WEEK HIGH
15.88
52 WEEK LOW
1.390
MARKET CAP
2.34B
P/E (TTM)
-53.5582
1D
5D
1M
3M
1Y
5Y
1D
Sellas Life Sciences presents preclinical data on SLS009 at AACR Conference
TipRanks · 3d ago
SELLAS Life Sciences Announces Preclinical Data Demonstrating SLS009 Synergy And Activity In MYC-Amplified Pancreatic Cancer Models
Benzinga · 3d ago
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
Barchart · 3d ago
Sellas Life Sciences: Valued For Perfection, REGAL Trial Success Probability Priced In
Seeking Alpha · 09/21 12:37
Weekly Report: what happened at SLS last week (0914-0918)?
Weekly Report · 09/21 09:28
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
Seeking Alpha · 09/20 18:57
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Seeking Alpha · 09/17 13:45
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 09/14 12:06
More
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

Webull offers Sellas Life Sciences Group Inc stock information, including NASDAQ: SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.